BiovaxID™ idiotype vaccination: Active immunotherapy for follicular lymphoma

Expert Review of Vaccines

Volumn 6, Issue 3, 2007, Pages 307-317

  Flowers, Christopher R ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Active; Cancer vaccine; Follicular; Immunoglobulin idiotypes; Immunology; Immunotherapy; Lymphoma; Therapy

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE; BCG VACCINE; BIOVAXID; CD20 ANTIBODY; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FAVID; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN IDIOTYPE; IMMUNOGLOBULIN IDIOTYPE KEYHOLE LIMPET HEMOCYANIN CONJUGATE; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; METHOTREXATE; MITOXANTRONE; MYVAX; PLACEBO; PREDNISONE; PROCARBAZINE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; CANCER VACCINE; HEMOCYANIN; IMMUNOLOGICAL ADJUVANT; KEYHOLE-LIMPET HEMOCYANIN;

ACTIVE IMMUNIZATION; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DENDRITIC CELL; DISEASE FREE SURVIVAL; DRUG COST; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; FOLLICULAR LYMPHOMA; HUMAN; HUMORAL IMMUNITY; HYBRIDOMA; IMMUNE RESPONSE; IMMUNOSTIMULATION; INJECTION SITE REACTION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT; IMMUNOLOGY; PHASE 3 CLINICAL TRIAL;

ADJUVANTS, IMMUNOLOGIC; CANCER VACCINES; CLINICAL TRIALS, PHASE III; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMOCYANIN; HUMANS; IMMUNOGLOBULIN IDIOTYPES; LYMPHOMA, FOLLICULAR;

EID: 34250353084     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.3.307     Document Type: Review

References (50)

1. Society AC. Cancer Facts & Figures 2006. American Cancer Society, GA, USA (2006).
2. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues. IARC Press, Lyon, France (2001).
3. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin. Oncol. 20(5 Suppl. 5), 75-88 (1993).
4. Orina JN, Moore SG, Lechowicz MJ, Flowers CR. Determining the benefits of chemotherapy for achieving complete response in patients with untreated advanced stage follicular lymphoma: a systematic review and meta-analysis. ASH Annual Meeting Abstracts 106(11), 290 (2005).
5. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J. Clin. Oncol. 23(33), 8447-8452 (2005).
6. Zelenetz AD, Advani RH, Buadi F et al. NCCN: non-Hodgkin's lymphoma. NCCN Clinical Practice Guidelines in Oncology (2006).
7. Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin. Oncol. 26(5 Suppl. 14), 88-96 (1999).
8. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105(4), 1417-1423 (2005).
9. Friedberg JW, Huang J, Dillon H et al. Initial therapeutic strategy in follicular lymphoma (FL): an analysis from the National LymphoCare Study (NLCS). ASCO Annual Meeting Proceedings. Abstract 7527(2006).
10. Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J. Clin. Oncol. 23(26), 6421-6428 (2005). • Provides a recent review of current immunotherapeutic approaches to the treatment of non-Hodgkin's lymphoma, contrasting passive and active forms of immunotherapy.
11. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346(4), 235-242 (2002).
12. Pfreundschuh MG, Trumper L, Ma D et al. Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab - early stopping after the first interim analysis. Proc. Am. Soc. Clin. Oncol. Abstract 6500 (2004).
13. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16(8), 2825-2833 (1998).
14. Liu Q, Fayad L, Cabanillas F et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J. Clin. Oncol. 24(10), 1582-1589 (2006).
15. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J. Clin. Oncol. 23(22), 5019-5026 (2005).
16. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J. Clin. Oncol. 22(23), 4711-4716 (2004).
17. Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12), 3725-3732 (2005).
18. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med. 306(9), 517-522 (1982).
19. Thielemans K, Maloney DG, Meeker T et al. Strategies for production of monoclonal anti-idiotype antibodies against human B cell lymphomas. J. Immunol. 133(1), 495-501 (1984).
20. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surfaceimmunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327(17), 1209-1215 (1992).
21. Bendandi M. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma. Expert Rev. Anticancer Ther. 1(1), 65-72 (2001).
22. Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5(10), 1171-1177 (1999).
23. Weng WK, Czerwinski D, Levy R. Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy. Blood 109(3), 951-953 (2007).
24. Hsu FJ, Caspar CB, Czerwinski D et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 89(9), 3129-3135 (1997).
25. Dermime S, Aljurf MD. Current advances, problems and prospects for vaccine-based immunotherapy in follicular non-Hodgkin's lymphoma. Leuk. Lymphoma 46(4), 497-507 (2005).
26. Hurvitz SA, Timmerman JM. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId. Expert Opin. Biol. Ther. 5(6), 841-852 (2005). • Examines the development history and current status of lymphoma idiotype vaccines.
27. Stevenson GT, Elliott EV, Stevenson FK. Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target. Fed. Proc. 36(9), 2268-2271 (1977).
28. Stevenson FK, Gordon J. Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation. J. Immunol. 130(2), 970-973 (1983).
29. Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN. Myeloma proteins as tumor-specific transplantation antigens. Proc. Natl Acad. Sci. USA 69(6), 1540-1544 (1972).
30. Kaminski MS, Kitamura K, Maloney DG, Levy R. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J. Immunol. 138(4), 1289-1296 (1987).
31. Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl Acad. Sci. USA 93(20), 10972-10977 (1996).
32. Vose JM. Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach. Hematol. Oncol. 24(2), 47-55 (2006).
33. Timmerman J, Czerwinski D, van Beckhoven A et al. A Phase 1/2 trial to evaluate the immunogenicity of recombinant idiotype protein vaccines for the treatment of non-Hodgkin's lymphoma (NHL). ASH Annual Meeting Abstracts. Abstract 2481 (2000).
34. Timmerman JM, Vose J, Levy R, Mayo M, Denney D. Long-term follow-up of patients treated in a Phase 2 trial with MyVax(R) personalized immunotherapy (recombinant Id-KLH with GM-CSF) after chemotherapy as initial treatment for follicular non-Hodgkin's lymphoma (NHL). ASH Annual Meeting Abstracts 106(11), 2438 (2005).
35. Koc ON, Redfern C, Wiernik PH et al. Id/KLH vaccine (FavId™) following treatment with rituximab: an analysis of response rate improvement (RRI) and time-to-progression (TTP) in follicular lymphoma (FL). ASH Annual Meeting Abstracts. 104(11), 587 (2004).
36. Inoges S, Rodriguez-Calvillo M, Zabalegui N et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J. Natl Cancer Inst. 98(18), 1292-1301 (2006).
37. Levy R, Dilley J. Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization. Proc. Natl Acad. Sci. USA 75(5), 2411-2415 (1978).
38. George AJ, Tutt AL, Stevenson FK. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J. Immunol. 138(2), 628-634 (1987).
39. Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J. Immunol. 145(3), 1029-1036 (1990).
40. Tao MH, Levy R. Idiotype/granulocytemacrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362(6422), 755-758 (1993).
41. Timmerman J, Levy R, Czerwinski D, Ingolia D, Denney DW, Kunkel L. A phase 2 trial to evaluate the efficacy of recombinant idiotype vaccines in untreated follicular non-Hodgkin's lymphoma in the "watch-and-wait" period. Proc. Am. Soc. Clin. Oncol. 21, 13 (2002).
42. Leonard JP, Mason K, Theriault T et al. Preliminary immune response (IR) results of a phase 2 study with idiotype (Id) immunotherapy after treatment with CVP and rituximab for follicular non-Hodgkin's lymphoma (FL). J. Clin. Oncol. 24(20 Suppl.), 7529 (2006).
43. Orina JN, Flowers CR. Determining the benefits of rituximab + chemotherapy for patients with untreated follicular lymphoma: a comprehensive meta-analysis. ASH Annual Meeting Abstracts 108(11), 3330 (2006).
44. Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 92(4), 1184-1190 (1998).
45. Timmerman JM, Czerwinski DK, Davis TA et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99(5), 1517-1526 (2002).
46. Neelapu SS, Baskar S, Gause BL et al. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin. Cancer Res. 10(24), 8309-8317 (2004).
47. Cohen S, Haimovich J, Hollander N. B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice. J. Immunother. 28(5), 461-466 (2005).
48. Savelyeva N, King CA, Vitetta ES, Stevenson FK. Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help. Proc. Natl Acad. Sci. USA 102(31), 10987-10992 (2005).
49. Czuczman MS, Grillo-Lopez AJ, McLaughlin P et al. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann. Oncol. 12(1), 109-114 (2001).
50. Bendandi M. Anti-idiotype vaccines for human follicular lymphoma. Leukemia 14(8), 1333-1339 (2000).